Related Experiment Videos
Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma
Thorax
|October 1, 1980
Summary
Adjuvant Bacillus Calmette-Guérin (BCG) immunotherapy significantly reduced recurrence rates in patients with resected squamous cell bronchial carcinoma (SCC). This immune stimulation improved patient prognosis and cellular immune reactivity, particularly in those with minimal residual disease.
Area of Science:
- Oncology
- Immunotherapy
- Thoracic Surgery
Background:
- Lung resection is a primary treatment for resectable lung cancer.
- Adjuvant therapies are explored to improve outcomes in patients with resected lung cancer, especially those with squamous cell carcinoma (SCC).
- Bacillus Calmette-Guérin (BCG) is an immunotherapy agent with potential anti-tumor effects.
Purpose of the Study:
- To evaluate the efficacy of adjuvant Bacillus Calmette-Guérin (BCG) immunotherapy in patients with resected locally advanced squamous cell bronchial carcinoma (SCC).
- To assess the impact of BCG on recurrence rates and immune reactivity.
- To compare systemic BCG administration with combined systemic and intrapleural treatment.
Main Methods:
- A randomized controlled trial involving 54 patients with resected SCC and 3 with adenocarcinoma (AC).
- SCC patients received either adjuvant BCG via scarification (BCG-A), combined intrapleural and scarification BCG (BCG-B), or no adjuvant treatment (control).
- Immune reactivity was monitored using PPD skin tests, and follow-up ranged from 3 to 51 months.
Main Results:
- BCG-treated SCC groups showed statistically significant reductions in recurrence rates compared to controls.
- No significant difference in outcomes was observed between systemic BCG and combined systemic/intrapleural BCG treatments.
- BCG treatment led to a pronounced increase in PPD skin reactivity, correlating with a more favorable clinical outcome in SCC patients.
- All three AC patients treated with BCG relapsed within nine months.
Conclusions:
- Adjuvant BCG immunotherapy improves prognosis in selected patients with minimal residual squamous cell bronchial carcinoma (SCC) after resection.
- Intrapleural BCG administration did not offer additional prognostic benefit over systemic treatment.
- Increased cellular immune reactivity, as indicated by PPD skin tests, is associated with a favorable clinical outcome in BCG-treated SCC patients.